Table 1.
General clinicopathological characteristics of patients with and without ACT before and after PSM
| Characteristics | Before PSM (N = 1050) |
After PSM (N = 650) |
||||
|---|---|---|---|---|---|---|
| Without ACT (N = 715) | With ACT (N = 335) | P | Without ACT (N = 325) | With ACT (N = 325) | P | |
| Sex, n (%) | ||||||
| Male | 491 (68.7) | 238 (71.0) | 0.437 | 227 (69.8) | 232 (71.4) | 0.667 |
| Female | 224 (31.3) | 97 (29.0) | 98 (30.2) | 93 (28.6) | ||
| Age (years) | ||||||
| Mean ± SD | 60.9 ± 9.7 | 57.4 ± 9.4 | <0.001 | 57.7 ± 10.0 | 57.9 ± 8.9 | 0.782 |
| Median (min, max) | 61.0 (29, 90) | 58.0 (24, 79) | 58.0 (29, 83) | 58.0 (25, 79) | ||
| ≤60 | 341 (47.7) | 204 (60.9) | <0.001 | 198 (60.9) | 195 (60.0) | 0.810 |
| >60 | 374 (52.3) | 131 (39.1) | 127 (39.1) | 130 (40.0) | ||
| Tumour size (cm) | ||||||
| Mean ± SD | 3.3 ± 1.1 | 3.5 ± 1.1 | 0.019 | 3.4 ± 1.2 | 3.5 ± 1.1 | 0.144 |
| Median (min, max) | 3.5 (0.5, 5.0) | 4.0 (0.6, 5.0) | 3.5 (1.0, 5.0) | 4.0 (0.6, 5.0) | ||
| ≤4 cm | 567 (79.3) | 256 (76.4) | 0.290 | 250 (76.9) | 249 (76.6) | 0.926 |
| >4 cm | 148 (20.7) | 79 (23.6) | 75 (23.1) | 76 (23.4) | ||
| Anatomical type, n (%) | ||||||
| Central | 82 (11.5) | 41 (12.2) | 0.718 | 39 (12.0) | 40 (12.3) | 0.904 |
| Peripheral | 633 (88.5) | 294 (87.8) | 286 (88.0) | 285 (87.7) | ||
| Tumour location, n (%) | ||||||
| RUL | 214 (29.9) | 102 (30.4) | 0.419 | 93 (28.6) | 100 (30.8) | 0.962 |
| RML | 63 (8.8) | 31 (9.3) | 31 (9.5) | 30 (9.2) | ||
| RLL | 142 (19.9) | 57 (17.0) | 54 (16.6) | 56 (17.2) | ||
| LUL | 191 (26.7) | 82 (24.5) | 87 (26.8) | 80 (24.6) | ||
| LLL | 105 (14.7) | 63 (18.8) | 60 (18.5) | 59 (18.2) | ||
| Comorbidity, n (%) | ||||||
| No | 543 (75.9) | 265 (79.1) | 0.257 | 248 (76.3) | 255 (78.5) | 0.512 |
| Yes | 172 (24.1) | 70 (20.9) | 77 (23.7) | 70 (21.5) | ||
| Smoking history, n (%) | ||||||
| Never | 319 (44.6) | 140 (41.8) | 0.592 | 144 (44.3) | 135 (41.5) | 0.586 |
| Current | 309 (43.2) | 156 (46.6) | 138 (42.5) | 151 (46.5) | ||
| Quit | 87 (12.2) | 39 (11.6) | 43 (13.2) | 39 (12.0) | ||
| Surgical resectiona, n (%) | ||||||
| Lobectomy | 621 (86.9) | 302 (90.1) | 0.263 | 290 (89.2) | 292 (89.8) | 0.890 |
| Bilobectomy | 43 (6.0) | 17 (5.1) | 19 (5.8) | 17 (5.2) | ||
| Pneumonectomy | 40 (5.6) | 10 (3.0) | 8 (2.5) | 10 (3.1) | ||
| Sublobar resection | 11 (1.5) | 6 (1.8) | 8 (2.5) | 6 (1.98) | ||
| Histology, n (%) | ||||||
| Adenocarcinoma | 453 (63.4) | 207 (61.8) | 0.048 | 208 (64.0) | 200 (61.5) | 0.809 |
| Squamous cell carcinoma | 226 (31.6) | 98 (29.3) | 92 (28.3) | 98 (30.2) | ||
| Adenosquamous carcinoma | 18 (2.5) | 15 (4.5) | 12 (3.7) | 14 (4.3) | ||
| Neuroendocrine carcinoma | 11 (1.5) | 10 (3.0) | 7 (2.2) | 9 (2.8) | ||
| Sarcomatoid carcinoma | 2 (0.3) | 3 (0.9) | 1 (0.3) | 3 (0.9) | ||
| Mucoepidermoid carcinoma | 4 (0.6) | 1 (0.3) | 4 (1.2) | 1 (0.3) | ||
| Pleomorphic carcinoma | 0 | 1 (0.3) | 0 | 0 | ||
| Basaloid carcinoma | 1 (0.1) | 0 | 1 (0.3) | 0 | ||
| Cell differentiation, n (%) | ||||||
| Well | 61 (8.5) | 24 (7.2) | 0.148 | 25 (7.7) | 24 (7.4) | 0.925 |
| Moderate | 337 (47.1) | 141 (42.1) | 142 (43.7) | 138 (42.5) | ||
| Poor | 317 (44.3) | 170 (50.7) | 158 (48.6) | 163 (50.2) | ||
| Vascular invasion, n (%) | ||||||
| No | 687 (96.1) | 317 (94.6) | 0.282 | 309 (95.1) | 310 (95.4) | 0.854 |
| Yes | 28 (3.9) | 18 (5.4) | 16 (4.9) | 15 (4.6) | ||
| Visceral pleural involvement, n (%) | ||||||
| No | 176 (24.6) | 82 (24.5) | 0.770 | 83 (25.5) | 79 (24.3) | 0.911 |
| Yes | 423 (59.2) | 195 (58.2) | 191 (58.8) | 192 (59.1) | ||
| NA | 116 (16.2) | 58 (17.3) | 51 (15.7) | 54 (16.6) | ||
| EGFR statusa, n (%) | ||||||
| Wild-type | 203 (61.9) | 126 (67.0) | 0.243 | 91 (61.5) | 123 (67.2) | 0.279 |
| Mutations | 125 (38.1) | 62 (33.0) | 57 (38.5) | 60 (32.8) | ||
| Treatment after recurrenceb, n (%) | ||||||
| No | 54 (48.6) | 29 (39.7) | 0.234 | 25 (48.1) | 26 (37.1) | 0.226 |
| Yes | 57 (51.4) | 44 (60.3) | 27 (51.9) | 44 (62.9) | ||
ACT, adjuvant chemotherapy; EGFR epidermal growth factor receptor; LLL, left lower lobe; LUL, left upper lobe; NA, not available; PSM, propensity score matching; RLL, right lower lobe; RML, right middle lobe; RUL, right upper lobe; SD, standard deviation.
a
Excluding patients without EGFR status record.
b
Excluding patients without recurrence.